Financial news, markets, and business updates
Bristol Myers Squibb receives FDA clearance for a novel myeloma treatment, while PBMs shift towards greater price transparency with TrumpRx comparisons.
Bristol Myers Squibb's approval of Zenbexus for multiple myeloma highlights its new drug class, while a lawsuit over delayed approvals remains unresolved.
Valisure is suing U.S. Pharmacopeia, alleging false claims about its drug testing methods and an attempt to undermine its reputation.
Bristol Myers Squibb's Zenbexus, a groundbreaking oral therapy for multiple myeloma, has gained FDA approval, marking a significant milestone in treatment options.
The CMS's recent ruling against funding pediatric gender-affirming treatment could face robust legal challenges, impacting future healthcare practices.
Today, vehicles monitor driver behavior, feeding data to insurers who adjust premiums based on the findings.
Community connections are vital for health yet overlooked in the U.S. and U.K. healthcare funding and discussions.
Commure has suspended payments under its referral program tied to AI products, just days before a critical investigation was published.
Splitting the MMR vaccine could lead to missed doses and increased illness among children, echoing past lessons from vaccine history.
FDA nixes a radiopharma drug by ITM Isotope Technologies, while Hims & Hers plans to enter the peptides market amidst evolving regulations.
MoonLake Immunotherapeutics faces scrutiny for vague disclosures on its autoimmune drug candidate, raising questions about its trial results’ credibility.
Nurses are increasingly spotlighting the risks of clinical AI, advocating for a collaborative approach to its development and deployment in healthcare.
Medicare's “Bridge” program aims to lower costs for GLP-1 medications, yet its complexity may hinder patient access to affordable treatments.
The FDA has rejected ITM-11 due to manufacturing concerns, hindering its potential as a competitor to Novartis’ treatment for rare neuroendocrine tumors.
The FDA now requires manufacturers to disclose food additive details, enhancing oversight for substances previously lacking regulation.
Replimune's new melanoma treatment gains FDA approval, while a Medicare policy change delays price negotiations for AbbVie drugs.
As Boston's biotech sector grapples with talent migration to California, new discoveries in Alzheimer's research signal both change and opportunity.
Felix Wong's biotech startup thrives in California's culture despite his Massachusetts roots and impressive academic pedigree.
Replimune's advanced melanoma drug, RP1, receives FDA approval after a challenging path, bringing hope to patients with a hefty price tag.
The FDA has recently approved a new therapeutic drug and a vaccine, shaping the future direction of biotechnology and addressing pressing health needs.